Investor News

Exevir Bio awarded €1.6M grant for Dengue research

The grant will enable pre-clinical research towards prophylactic and therapeutic solutions for dengue

VIB spin-off company ExeVir Bio today announced it has been awarded a two-year R&D grant of €1.6 million by Flanders Innovation & Entrepreneurship (VLAIO) for pre-clinical research towards prophylactic and therapeutic solutions for dengue.

According to the WHO, dengue is one of the most important vector-borne viral diseases globally that is transmitted from mosquitoes to humans [1]. It is mainly spread by Aedes aegypti mosquitoes and, to a lesser extent, Aedes albopictus mosquitoes. In 2019, Dengue was listed by the WHO as a top ten global health threat [2]. It is caused by any of four dengue virus serotypes, each of which can cause dengue fever, and, in some cases, it can lead to deadly complications such as dengue hemorrhagic fever or dengue shock syndrome. The incidence of dengue has grown dramatically around the world in recent decades, fueled by climate change and urbanization leading to recent transmission in parts of mainland US and Europe. Dengue is a leading cause of fever in travelers returning to the US and Europe from endemic countries, and the incidence of dengue among travelers is generally underestimated [3][4].

The medical need remains very high as there are no specific antiviral therapeutics available for the disease, limiting the treatment options to relieving symptoms and preventing complications. While the current vaccines are a big step forward in protecting people, they are not 100% effective and cannot be used for all.

ExeVir is leveraging its unique, modular llama-derived antibody (VHH) technology platform to generate multi-specific antibodies for prophylaxis and treatment against infectious diseases, such as dengue. ExeVir’s technology will enable cross-reactivity against all four serotypes, have a dual mode of action, and be prophylactic and therapeutic with a sufficiently long treatment window.

Dr. Torsten Mummenbrauer, CEO of ExeVir: “We’re delighted with this support from the Flemish Government as it will help us with our research into using our powerful VHH technology to combat global health threats from infectious diseases beyond COVID-19.”

Alongside this dengue R&D project, ExeVir remains committed to its pioneering work in developing COVID-19 solutions for the millions of immunocompromised people who remain at high risk of severe morbidity or death from COVID-19 as they do not generate the same level of antibodies as immunocompetent people and could benefit from new multi-specific antibodies.

References

[1] https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue

[2] https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019

[3] https://www.cdc.gov/mmwr/volumes/69/wr/mm6906a1.htm

[4] https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.2.2001937

Lies Vanneste

Lies Vanneste

Investor Relations Manager, VIB

Share

Latest stories

Researchers discover clues for Alzheimer’s disease in hibernation

Researchers discover clues for Alzheimer’s disease in hibernation

Leuven, 12 November 2026 – Researchers at VIB and KU Leuven have discovered that hibernation triggers changes in brain cells that partially resemble those in Alzheimer’s disease. Studying golden hamsters, the team identified changes in gene expression across the hibernation cycle, which resemble those associated with the accumulation of amyloid plaques in Alzheimer’s. The findings, published in Science Advances, suggest that some early cellular changes associated with Alzheimer’s may also occur as part of a natural adaptive response, offering new ways to study the disease for therapy development.

press.vib.be

An inside look at a molecular switch that triggers inflammation

An inside look at a molecular switch that triggers inflammation

Ghent, 9 November 2026 – Researchers at VIB and Ghent University have uncovered how an important driver of inflammation is activated at the molecular level. Their findings, published in Science Immunology, also explain how a medicine used to treat a severe form of psoriasis blocks this inflammatory signal.

press.vib.be

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Researchers uncover why humans are more sensitive than other species to a brain developmental disease

Leuven, 4 November 2026 – Researchers at VIB and KU Leuven have uncovered how mutations in the ASPM gene disrupt the development of neural stem cells that help the human brain grow. This disruption explains how these mutations cause microcephaly, a condition characterized by an abnormally small brain and head, often accompanied by intellectual disability. The discovery, published in Developmental Cell, also sheds light on how differences in brain development can make humans more susceptible to certain genetic conditions than other mammals.

press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be